← Company library
Korea / Company briefSources checked 2026-11-15

Aprogen Biologics

A biosimilar developer with an Osong plant able to produce more than 2.8 million litres of antibodies a year.

Rituximab and trastuzumab biosimilars

Stage unconfirmed

Rituximab and trastuzumab biosimilars in regulatory and clinical stages.

Official role guide

Aprogen Biologics careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 에이프로젠바이오로직스 기업현황 ↗FnGuide 기업모니터 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable
  2. 에이프로젠, 세계 최대 관류식 연속배양 방식 공장 보유 ↗이투데이 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable